Altered angiogenesis in preeclampsia: Evaluation of a new test system for measuring placental growth factor

Clinical Chemistry and Laboratory Medicine

Volumn 45, Issue 11, 2007, Pages 1504-1510

  Schmidt, Markus ^a   Dogan, Canan ^a   Birdir, Cahid ^a   Callies, Rainer ^a   Kuhn, Ulrich ^a   Gellhaus, Alexandra ^a   Janetzko, Alfred ^b   Kimmig, Rainer ^a   Kasimir Bauer, Sabine ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b DRG Instruments GmbH   (Germany)

Author keywords

Angiogenesis; Fms like tyrosine kinase; Pathophysiology; Placental growth factor; Preeclampsia; Vascular endothelial growth factor

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 1; PLACENTAL GROWTH FACTOR;

ANGIOGENESIS; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATION COEFFICIENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PATHOGENESIS; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL;

ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 35649017276     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2007.316     Document Type: Article

References (41)

1. Conde-Agudelo A, Belizan JM, Diaz-Rossello JL. Epidemiology of fetal death in Latin America. Acta Obstet Gynecol Scand 2000;79:371-8.
2. Villar J, Say L, Gülmezoglu M, Merialdi M, Lindheimer M, Betran AP. Eclampsia and preeclampsia: a worldwide health problem for 2000 years. In: Critchley H, Mac Lean A, Poston L, Walker J, editors. Preeclampsia. London: RCOG Press, 2003:189-207.
3. Sibai BM, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005;365:785-99.
4. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 2005;308:1592-4.
5. National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Report. Am J Obstet Gynecol 2002;183:1-22.
6. Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol 2003;102:181-92.
7. Brown MA, Hague WM, Higgins J, Lowe S, McLowan L, Oats J, et al. The detection, investigation and management of hypertension in pregnancy: executive summary. Aust N Z J Obstet Gynaecol 2000;40:133-8.
8. Helewa ME, Burrows RF, Smith J, Williams K, Brain P, Rabkin SW. Report of the Canadian Hypertension Society consensus conference: 1. Definitions, evaluation and classification of hypertensive disorders in pregnancy. Can Med Assoc J 1997;157:715-25.
9. Myatt L. Role of placenta in preeclampsia. Endocrine 2002;19:103-11.
10. Dietl J. The pathogenesis of pre-eclampsia: new aspects. J Perinat Med 2000;28:464-71.
11. Pijnenborg R, Dixon G, Robertson WB, Brosens J. Trophoblast invasion of human deciduas from 8 to 18 weeks of pregnancy. Placenta 1980;1:3-19.
12. Zhou Y, Damsky CH, Fisher SJ. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? J Clin Invest 1997;99:2152-64.
13. Oudejans CB, Tjoa ML, Westerman BA, Mulders MA, Van Wijk IJ, Van Vugt JM. Circulating trophoblast in maternal blood. Prenat Diagn 2003;23:111-6.
14. Fisher SJ. The placental problem: linking abnormal cytotrophoblast differentiation to the maternal symptoms of preeclampsia. Reprod Biol Endocrinol 2004;2:53-6.
15. Zhou Y, Damsky CH, Chiu K, Roberts JM, Fisher SJ. Preeclampsia is associated with abnormal expression of adhesion molecules by invasive cytotrophoblasts. J Clin Invest 1993;91:950-60.
16. Lam C, Lim KH, Karamunanchi SA. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension 2005;46:1077-85.
17. Bdolah Y, Karumanchi A, Sachs BP. Recent advances in understanding of preeclampsia. Croat Med J 2005;46:728-36.
18. Gellhaus A, Schmidt M, Dunk C, Lye ST, Kimmig R, Winterhager E. Decreased expression of angiogenic regulators CYR61 (CCN1) and NOV (CCN3) in human placenta is associated with pre-eclampsia. Mol Hum Reprod 2006;12:389-99.
19. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
20. Zhou Y, Bellingard V, Feng KT, McMaster M, Fisher SJ. Human cytotrophoblasts promote endothelial survival and vascular remodeling through secretion of Ang2, PLGF, and VEGF-C. Dev Biol 2003;263:114-25.
21. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFLT-1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-58.
22. Zhou Y, McMaster M, Woo K, Janatpour M, Perry J, Karpanen T, et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 2002;160:1405-23.
23. Tsatsaris V, Goffin F, Munaut C, Brichant JF, Pignon MR, Noel A, et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 2003;88:5555-63.
24. Mac Gabhann F, Popel AS. Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells. Am J Physiol Heart Circ Physiol 2003;286:153-64.
25. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672-83.
26. Stepan H, Faber R, Dornhöfer N, Huppertz B, Robitzki A, Walther Th. New insights into the biology of preeclampsia. Biol Reprod 2006;74:772-6.
27. Schmidt M, Gellhaus A, Kasimir-Bauer S, Winterhager E, Kimmig R. Angiogenic factors during pregnancy: indicators of preeclampsia. Geburtsh Frauenheilk 2007;67:228-35.
28. Shibuya M, Yamagucgi S, Yamane A, Ikeda T, Tojo A, Matsushime H, et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 1990;5:519-24.
29. Terman BI, Dougher-Vermazen M, Carrion ME. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992;187:1579-86.
30. Huppertz B, Peters LL. Vascular biology in implantation and placentation. Angiogenesis 2005;8:157-67.
31. Mayhew TM. Fetoplacental angiogenesis during gestation is biphasic, longitudinal and occurs by proliferation and remodelling of vascular endothelial cells. Placenta 2002;23:742-50.
32. Bersinger NA, Odegard RA. Second and third trimester serum levels of placental proteins in preeclampsia and small-for-gestational age pregnancies. Acta Obstet Gynecol Scand 2004;83:37-45.
33. Krauss T, Pauer HU, Augustin HG. Prospective analysis of placenta growth factor (PLGF) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia. Hypertens Pregnancy 2004;23:101-11.
34. Stepan H, Unversucht A, Wessel N, Faber R. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 2007;49:818-24.
35. Polliotti BM, Fry AG, Saller DN, Mooney RA, Cox C, Miller RK. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol 2003;101:1266-74.
36. Taylor RN, Grimwood J, Taylor RS, McMaster MT, Fisher SJ, North RA. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 2003;188:177-82.
37. Ohkuchi, A, Hirashima C, Matsubara S, Suzuki H, Takahashi K, Arai F, et al. Alterations in placental growth factor levels before and after the onset of preeclampsia are more pronounced in women with early onset severe preeclampsia. Hypertens Res 2007;30:151-9.
38. Duley L, Henderson-Smart DJ, Knight M, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2004;CD004659.
39. Conde-Agudelo A, Villar J, Lindheimer M. World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol 2004;104:1367-91.
40. Muller PR, James AH, Murtha AP, Yonish B, Jamison MG, Dekker G. Circulating angiogenic factors and abnormal uterine artery Doppler velocimetry in the second trimester. Hypertens Pregnancy 2006;25:183-92.
41. Schlembach D, Wallner W, Sengenberger R, Stiegler E, Mortl M, Beckmann MW, et al. Angiogenic growth factor levels in maternal and fetal blood: correlation with Doppler ultrasound parameters in pregnancies complicated by pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol 2007;29:407-13.